Archive

This is my archive

Eccogene Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases

Eccogene will receive initial upfront payment of $185 million. Eccogene is also eligible to receive up to $1.825 billion in future clinical, regulatory, and commercial milestones, as well as royalty payments. AstraZeneca will receive an exclusive license to develop and commercialize ECC5004 in all territories except China. In China, Eccogene and AstraZeneca will partner for… Read More

Phanes Therapeutics, Inc. Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate PT886 in Combination with KEYTRUDA® (pembrolizumab)

PT886 is Phanes’ first-in-class bispecific antibody targeting claudin 18.2 and CD47; KEYTRUDA® (pembrolizumab) is Merck’s anti-PD-1 The clinical trial collaboration will focus on evaluating PT886 in combination with KEYTRUDA® for the treatment of claudin 18.2 positive gastric or gastroesophageal junction adenocarcinomas PT886 is also being studied for the treatment of pancreatic cancer… Read More

Allecra Therapeutics and ADVANZ PHARMA Sign Exclusive License and Supply Agreement for Allecra’s Antibiotic Cefepime/enmetazobactam in Europe

Allecra receives upfront, development and commercial milestone payments, in addition to double-digit royalties ADVANZ gains commercial rights for cefepime/enmetazobactam in the European Union, the United Kingdom, Switzerland, and Norway Cefepime/enmetazobactam has completed a Phase III clinical trial against standard of care in treating complicated urinary tract infection, including acute pyelonephritis1… Read More

Clover and GSK Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with Pandemic Adjuvant System

CHENGDU, China, London, UK – 24 February 2020 – Clover Biopharmaceuticals, a China based global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, announced today that it has entered into a research collaboration with GSK for its protein-based coronavirus vaccine candidate (COVID-19 S-Trimer). GSK will provide Clover with its pandemic adjuvant… Read More